KAI Initiates Third Phase 2a Study to Develop KAI-1678 for the Treatment of Neuropathic Pain

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated a... [more]

View complete Press Release article